Launched in 1997, the Pharmapack Awards celebrate the latest innovations from packaging companies within the drugs, medical devices, health products and veterinary drugs sectors.
The Pharmapack Awards recognise innovations that have improved drug efficacy, user safety or reduced the environmental impact.
Pharmaceutical, veterinary, biopharma or OEM companies - you can also co-apply with your manufacturer or packaging developer if the innovation is a collaborative one. That way, both companies get recognized for their work!
It should have received Market authorization from a qualified national authority for a newly commercialized medicinal product after December 2019. The product qualification needs to feature an innovative packaging or drug delivery solution. The candidates in this category will be evaluated by a jury of independent pharmacists, physicians and experts in patient-centric and sustainable packaging.
Basic Design
Ease of use
Intuitiveness of Use & Appeal
Presentation of Patient Information (PIL)
Carbon footprint of the new product
Increased recyclability
Intuitiveness of Use & Appeal
Environmental awareness
in partnership with:
Click HERE to check the application requirements and submit your application before 30 June 2021.
Entries for the Health Product category are free of charge.
The candidate is required to send 8 product samples by post before 30 June 2021. If no sample is provided, the entry will be disregarded.
Sample shipping address:
Informa Markets - Pharmapack Awards
April Hung
De Entrée 73
1101 BH Amsterdam
The Netherlands
For 2021, we have 6 distinct recognitions. Click on each category to learn more!
Recognising innovative approaches to safe and efficacious drug administration, including but not limited to; ophthalmic, parenteral, oral, respiratory, transdermal and topical drug delivery solutions.
• Innovation: Does the entry meet an unmet need, or introduce a new idea, device, method or novelty to the market?
• Patient Experience: Does the entry improve patient adherence, experience and outcomes?
• Ease of Use: Does the entry promote easy and safe administration by patients or HCPs?
• Sustainability: Is the product reusable, ecologically designed or easily recyclable?
• Added Value: Does it offer a competitive advantage in the market and within its category? Is it a cost-effective solution? Does it exhibit flexibility, adaptability or a collaborative approach to development?
Recognising innovation in the development of connected devices, IoT applications and wearable technologies, including but not limited to; auto-injectors, auto-inhalers, remote monitors (glucose, coagulation etc), wearable defibrillators, early detection devices and EMG sensors.
• Innovation: Does the entry meet an unmet need, or introduce a new idea, device, method or novelty to the market?
• Patient Experience: Does the entry improve patient adherence, experience and outcomes?
• Ease of Use: Does the entry promote easy and safe administration by patients or HCPs?
• Sustainability: Is the entry reusable, ecologically designed or easily recyclable?
• Added Value: Does the entry offer tangible benefits in the collection, monitoring and processing of patient data? Does it offer a competitive advantage in the market and within its category? Is it a cost-effective solution? Does it exhibit flexibility, adaptability or a collaborative approach to development?
Recognising innovation in technologies, products, materials, and services relating to primary packaging solutions for finished drug forms which safeguard products from manufacture to point of use. Including, but not limited to; vials, syringes, ampoules, bottles, container liners, flasks, tubes, blister packs, tamper-proof packaging, senior-friendly packaging, child-resistant packaging, and smart packaging.
• Innovation: Does the entry meet an unmet need, or introduce a new idea, approach, method or novelty to the market?
• Patient Experience: Does the entry improve patient adherence, experience and outcomes?
• Fit for Purpose: Does the entry adequately protect the drug product for which it is designed? Does it prevent minimal extractable and leachable risk?
• Sustainability: Is the product reusable, ecologically designed or easily recyclable?
• Added Value: Does it offer a competitive advantage in the market and within its category? Is it a cost-effective solution? Does it exhibit flexibility and adaptability?
Recognising innovation in technologies, products, materials, and services related to the promotion of sustainable primary, secondary or tertiary packaging solutions for finished drug forms which safeguard products from manufacture to point of use. Including, but not limited to; containers, cartons, pallets, blister cards, shrink-wrapped bundles, labelling systems, tamper-proof packaging, senior-friendly packaging, child-resistant packaging, and smart packaging solutions.
• Innovation: Does the entry meet an unmet need, or introduce a new idea, approach, method or novelty to the market?
• Patient Experience: Does the entry improve patient adherence, experience and outcomes?
• Fit for Purpose: Does the entry adequately protect the drug product for which it is designed? Does it offer benefits for branding and
product display?
• Sustainability: Is the product reusable, ecologically designed or easily recyclable? Does it demonstrably reduce the use of plastics and/or
other waste?
• Added Value: Does it offer a competitive advantage in the market and within its category? Is it a cost-effective solution? Does it exhibit flexibility, adaptability or a collaborative approach to development?
Recognising innovation in pharmaceutical packaging machinery, technology, and equipment. This category seeks to recognise both stand alone and integrated solutions which promote efficiency, cost effectiveness and sustainable approaches to the assembly and packaging of pharmaceutical products.
• Innovation: Does the entry meet an unmet need, or introduce a new idea, approach, method, or novelty to the market?
• Fit for Purpose: Does the entry offer efficient and cost-effective solutions? Does it prioritise packaging design?
• Sustainability: Does the entry promote a sustainable approach?
• Added Value: Does it offer a competitive advantage in the market and within its category? Is it a cost-effective solution? Does it exhibit flexibility, adaptability or a collaborative approach to development?
Innovation in technologies, products, processes, and services for ensuring the safe handling and tracking of drug substances, raw materials, and finished drug products including, but not limited to, supply chain, audits, temperature-controlled logistics, transport services, track and trace, shipping containers, and distribution channels.
• Innovation: Does the entry meet an unmet need, or introduce a new idea, approach, method or novelty to the market?
• Patient Experience: Does the entry improve patient adherence, experience and outcomes?
• Fit for Purpose: Does the entry adequately protect the drug product for which it is designed?
• Sustainability: Does the entry exhibit a sustainable approach or minimise waste?
• Added Value: Does it offer a competitive advantage in the market and within its category? Is it a cost-effective solution? Does it exhibit flexibility, adaptability or a collaborative approach to development?
Reserved especially for Pharmapack 2021 exhibitors, the Exhibitor Awards allow entrants to present their latest innovative solutions, in proof of concept or prototype stage, in packaging materials, primary or secondary packaging, cool chain packaging and drug delivery solutions, new processing or machinery solution which were recently launched or patented since January 2020.
To be considered, exhibitors need to purchase Innovation Package, and complete this form with their submission.
Awards in this category will be evaluated by a jury of decision-makers involved in R&D and in the selection of packaging and drug delivery solutions for pharmaceutical and biopharmaceutical companies.
Please contact your account manager for Innovation Gallery and Pharmapack Awards entry options. Deadline for submission: 30 June 2021.